000291288 001__ 291288
000291288 005__ 20250127154942.0
000291288 0247_ $$2doi$$a10.3390/cancers16122198
000291288 0247_ $$2pmid$$apmid:38927904
000291288 0247_ $$2altmetric$$aaltmetric:165054015
000291288 037__ $$aDKFZ-2024-01371
000291288 041__ $$aEnglish
000291288 082__ $$a610
000291288 1001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b0$$eFirst author$$udkfz
000291288 245__ $$aSurvival in Elderly Ovarian Cancer Remains Challenging in the Nordic Countries.
000291288 260__ $$aBasel$$bMDPI$$c2024
000291288 3367_ $$2DRIVER$$aarticle
000291288 3367_ $$2DataCite$$aOutput Types/Journal article
000291288 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1737989349_15069
000291288 3367_ $$2BibTeX$$aARTICLE
000291288 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291288 3367_ $$00$$2EndNote$$aJournal Article
000291288 500__ $$a#EA:Z999#
000291288 520__ $$aDespite treatment having improved through intensive surgical procedures and chemotherapy-and more recently, targeted therapies-ovarian cancer is the most fatal female cancer. As such, we wanted to analyze age-specific survival trends for ovarian cancer in Denmark, Finland, Norway and Sweden over the past 50 years, with a special aim of comparing survival development between the age groups.We modelled survival data from the NORDCAN database for 1-, 5- and conditional 5/1-year relative (between years 1 and 5) survival for ovarian cancer from 1972 to 2021.Young patients had a 70% 5-year survival while the survival was only 30% for the oldest patients. Conditional survival showed that survival between years 1 and 5 did not improve for patients older than 60 years throughout the 50-year period, during which time the gaps between the youngest and the oldest patients widened.Improvement in 1-year survival was so large that it masked the modest development between years 1 and 5, resulting in a widening age disparity in 5-year survival. The current treatment practices, which appear increasingly effective for younger patients, have not helped remedy the large age differences in ovarian cancer survival. Early detection methods and therapeutic innovations are urgently needed, and aged patients need a special focus.
000291288 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000291288 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291288 650_7 $$2Other$$acarboplatin cancer control
000291288 650_7 $$2Other$$aprognosis
000291288 650_7 $$2Other$$arelative survival
000291288 650_7 $$2Other$$atreatment
000291288 7001_ $$aZitricky, Frantisek$$b1
000291288 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b2$$udkfz
000291288 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b3
000291288 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers16122198$$gVol. 16, no. 12, p. 2198 -$$n12$$p2198$$tCancers$$v16$$x2072-6694$$y2024
000291288 8564_ $$uhttps://inrepo02.dkfz.de/record/291288/files/cancers-16-02198.pdf$$yRestricted
000291288 8564_ $$uhttps://inrepo02.dkfz.de/record/291288/files/cancers-16-02198.pdf?subformat=pdfa$$xpdfa$$yRestricted
000291288 909CO $$ooai:inrepo02.dkfz.de:291288$$pVDB
000291288 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000291288 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000291288 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000291288 9141_ $$y2024
000291288 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000291288 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000291288 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000291288 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000291288 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000291288 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000291288 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000291288 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-07-31T16:07:06Z
000291288 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000291288 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000291288 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000291288 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000291288 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000291288 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000291288 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000291288 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000291288 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000291288 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000291288 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000291288 9201_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x0
000291288 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000291288 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000291288 9200_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x0
000291288 980__ $$ajournal
000291288 980__ $$aVDB
000291288 980__ $$aI:(DE-He78)Z999-20160331
000291288 980__ $$aI:(DE-He78)B062-20160331
000291288 980__ $$aI:(DE-He78)HD01-20160331
000291288 980__ $$aUNRESTRICTED